Clinical Trials in Arizona

Showing 7201-7220 of 16,770 trials

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

NCT04186637

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.

Advanced Solid TumorLymphoma

Alpine Immune Sciences, Inc.62 participantsStarted Jun 2020

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Lafayette, Indiana, United States +7 more locations

COMPLETEDPhase 231 miles

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01806571

This phase II trial studies how well daunorubicin hydrochloride, cytarabine, and nilotinib work in treating patients newly diagnosed with acute myeloid leukemia. Drugs used in chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving daunorubicin hydrochloride with cytarabine and nilotinib may kill more cancer cells.

Untreated Adult Acute Myeloid Leukemia

Mayo Clinic34 participantsStarted Mar 2015

Scottsdale, Arizona, United States • Rochester, Minnesota, United States

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Find Trials by Condition in Arizona

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

International Hernia Mesh Registry

Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors